GeoVax Labs, Inc.

Healthcare · Biotechnology · United States

Last price 0.1859 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.69M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine....